A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
Phase 2
60
about 2.5 years
18–75
2 sites in CA, MI
Why this study is shown
What this study is about
This trial is testing a treatment called lutikizumab for people with hidradenitis suppurativa (HS) or atopic dermatitis (AD). Participants will receive subcutaneous injections of lutikizumab and have regular visits, blood tests, and biomarker collections. It duration is expected to last up to 30 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lutikizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
subcutaneous
Primary: Number of Participants With Adverse Events (AEs)
Dermatology